138 related articles for article (PubMed ID: 6115283)
21. beta-Adrenoreceptor-blocking agents and the blood-brain barrier.
Cruickshank JM; Neil-Dwyer G; Cameron MM; McAinsh J
Clin Sci (Lond); 1980 Dec; 59 Suppl 6():453s-455s. PubMed ID: 7449299
[TBL] [Abstract][Full Text] [Related]
22. The interaction between H2-receptor antagonists and beta-adrenoceptor blockers.
Mutschler E; Spahn H; Kirch W
Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):51S-57S. PubMed ID: 6146340
[TBL] [Abstract][Full Text] [Related]
23. Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay.
Wellstein A; Palm D; Belz GG; Leopold G; Bühring KU; Pabst J
J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S41-5. PubMed ID: 2439797
[TBL] [Abstract][Full Text] [Related]
24.
Tieu A; Velenosi TJ; Kucey AS; Weir MA; Urquhart BL
Clin J Am Soc Nephrol; 2018 Apr; 13(4):604-611. PubMed ID: 29519953
[TBL] [Abstract][Full Text] [Related]
25. Atenolol determination by high-performance liquid chromatography and fluorescence detection.
Yee YG; Rubin P; Blaschke TF
J Chromatogr; 1979 Apr; 171():357-62. PubMed ID: 546856
[TBL] [Abstract][Full Text] [Related]
26. Changes in serum phosphate during beta-blockade in healthy men are not due to changes in the renal handling of phosphate.
Kayser L; Perrild H; Jørgensen B; Fogh-Andersen N; Mølholm Hansen JE
J Intern Med; 1989 Mar; 225(3):197-200. PubMed ID: 2649632
[TBL] [Abstract][Full Text] [Related]
27. Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol.
Gangji D; Juvent M; Niset G; Wathieu M; Degreve M; Bellens R; Poortmans J; Degre S; Fitzsimons TJ; Herchuelz A
Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):29S-35S. PubMed ID: 6146337
[TBL] [Abstract][Full Text] [Related]
28. CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies.
Dimenäs E; Dahlöf C; Olofsson B; Wiklund I
Br J Clin Pharmacol; 1989 Nov; 28(5):527-34. PubMed ID: 2574052
[TBL] [Abstract][Full Text] [Related]
29. Diazepam/beta-adrenoceptor antagonist interactions.
Hawksworth G; Betts T; Crowe A; Knight R; Nyemitei-Addo I; Parry K; Petrie JC; Raffle A; Parsons A
Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):69S-76S. PubMed ID: 6146341
[TBL] [Abstract][Full Text] [Related]
30. Binding of adrenergic beta-receptor antagonists to human serum albumin.
Appelgren C; Borg KO; Elofsson R; Johansson KA
Acta Pharm Suec; 1974 Sep; 11(4):325-32. PubMed ID: 4153285
[No Abstract] [Full Text] [Related]
31. Propranolol and metoprolol: Two comparable drugs with very different post-mortem toxicological profiles.
Kriikku P; Pelkonen S; Kaukonen M; Ojanperä I
Forensic Sci Int; 2021 Oct; 327():110978. PubMed ID: 34481114
[TBL] [Abstract][Full Text] [Related]
32. [Effect of hyperlipidemia on pharmacodynamics of propranolol and atenolol].
Telatyńska-Smieszek B; Wójcicki J; Droździk M; Gawrońska-Szklarz B; Sulzyc-Bielicka V; Sterna R
Pol Arch Med Wewn; 2004 Jan; 111(1):45-51. PubMed ID: 15088420
[TBL] [Abstract][Full Text] [Related]
33. The distribution of propranolol, pindolol and atenolol between human erythrocytes and plasma.
Taylor EA; Turner P
Br J Clin Pharmacol; 1981 Oct; 12(4):543-8. PubMed ID: 7295488
[TBL] [Abstract][Full Text] [Related]
34. Aiming for steady 24-hour plasma concentrations: a comparison of two calcium antagonist and beta-blocker combinations.
Eriksson M; Nyberg G; Lidman K; Olofsson B; Bergstrand R
Blood Press Suppl; 1993; 1():16-21. PubMed ID: 7909705
[TBL] [Abstract][Full Text] [Related]
35. Kinetic interactions of nadolol and propranolol with cimetidine.
Duchin KL; Stern MA; Willard DA; McKinstry DN
Br J Clin Pharmacol; 1984 Apr; 17(4):486-7. PubMed ID: 6721996
[No Abstract] [Full Text] [Related]
36. Direct injection of large volumes of plasma/serum on a new biocompatible extraction column for the determination of atenolol, propranolol and ibuprofen. Mechanisms for the improvement of chromatographic performance.
Hermansson J; Grahn A; Hermansson I
J Chromatogr A; 1998 Feb; 797(1-2):251-63. PubMed ID: 9542118
[TBL] [Abstract][Full Text] [Related]
37. Receptor occupancy in lumbar CSF as a measure of the antagonist activity of atenolol, metoprolol and propranolol in the CNS.
Kaila T; Marttila R
Br J Clin Pharmacol; 1993 May; 35(5):507-15. PubMed ID: 8099803
[TBL] [Abstract][Full Text] [Related]
38. Accumulation and adverse effects of metoprolol and propranolol after concurrent administration of cimetidine.
Kirch W; Spahn H; Köhler H; Mutschler E
Arch Toxicol Suppl; 1983; 6():379-83. PubMed ID: 6578746
[TBL] [Abstract][Full Text] [Related]
39. Enantiomeric separation and sensitive detection of propranolol, metoprolol and atenolol derivatized with a fluorogenic reagent, 4-(N-chloroformylmethyl-N-methyl)amino-7-N,N-dimethylaminosulf onyl-2,1, 3-benzoxadiazole (DBD-COCl), on cellulose chiral columns in the reversed-phase mode.
Yang X; Fukushima T; Santa T; Homma H; Imai K
Analyst; 1997 Nov; 122(11):1365-9. PubMed ID: 9474815
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol.
Vinceneux P; Canal M; Domart Y; Roux A; Cascio B; Orofiamma B; Larribaud J; Flouvat B; Carbon C
Int J Clin Pharmacol Ther Toxicol; 1986 Mar; 24(3):153-8. PubMed ID: 2870990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
